XXII 22nd Century Group Earnings per share growth in current year

22nd Century Group (XXII) is confronting pressure from tobacco behemoths and regulatory barriers by implementing autonomous warehouse logistics and smart supply chain planning. The 12-month earnings per share growth rate reflects revenue dynamics, where the current metric equals 0.00. The strategic focus on FDA patents for nicotine-free tobacco is establishing a monopoly status, providing the company with significant pricing power and a stable free cash flow.

XXII - 22nd Century Group Earnings growth in current year over the range 07/04/2022 - 11/15/2026

Financial and market metric breakdowns for 22nd Century (XXII)

- stock quotes and analyst forecast:

Share Price 22nd Century|XXII - Price Target Chart

- market capitalization data:

Market Value 22nd Century Group, Inc.|XXII - Total Company Value

- book capitalization indicators:

Equity per Share 22nd Century Group|XXII - Book Capitalization|Capitalization to Book Value Ratio xxiicentury.com|XXII - Cumulative Company Assets

- debt and liquidity details:

All Debt to Shareholders' Equity Ratio 22nd Century Group|XXII - Long-Term Debt to Capital|Short-Term Debt to Equity Ratio 22nd Century Group Inc.|XXII - Company Aggregate Debts|Debts to Book Value 22nd Century Group, Inc.|XXII - Company Long-Term Debt|Company Short-Term Indebtedness 22nd Century Group|Intermediate Liquidity Ratio xxiicentury.com

- earnings and market ratios statistics:

XXII - Net Income|Projected Future Earnings 22nd Century Group|XXII - Price to Earnings Ratio|Future Price to Earnings Multiple 22nd Century Group|XXII - Price/Earnings to Growth Multiple|Company Value to EBITDA 22nd Century Group Inc.|XXII - Operating profit before deduction of amortization|Earnings per share for the trailing year 22nd Century Group|XXII - Net earnings per share (EPS TTM)|Net earnings per share growth for the trailing year xxiicentury.com|XXII - Earnings per share growth in current year|Expected earnings per share trend next year 22nd Century Group

- sales volume and revenue information:

XXII - Company Revenue|Company Expected Sales Volume 22nd Century Group|XXII - Market Cap to Revenue|Forward P/S Multiple 22nd Century Group, Inc.

Fundamental valuation:XXII xxiicentury.com

Manufactured products of 22nd Century Group Inc.

This indicator captures the year-over-year dynamics of earnings per share, measuring the efficiency of capital generation for shareholders. By analyzing the annual EPS variability, one can assess the impact of FDA regulatory barriers and debt load on the financial stability of the 22nd Century Group (XXII) biotech business. A positive trend confirms the viability of the strategy, while stagnation signals risks of ineffective marketing.

Main competitors